Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HS-20089 + bevacizumab
- Development stage
- Unknown
- Lead developer
- Hansoh Pharmaceutical Group
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**HS-20089 + bevacizumab** is an investigational combination therapy in clinical trials for advanced solid tumors and certain gynecological malignancies. HS-20089 is an antibody-drug conjugate (ADC) composed of a humanized IgG1 monoclonal antibody targeting B7-H4 (VTCN1), conjugated to a topoisomerase I inhibitor via a protease-cleavable linker, aiming to deliver cytotoxic payloads to B7-H4-expressing tumor cells while sparing normal tissue[1][3][7]. Bevacizumab is a recombinant humanized monoclonal antibody that targets and neutralizes VEGF-A to inhibit angiogenesis in tumors[2][4]. The combination seeks to attack cancer cells directly via ADC payload cytotoxicity and disrupt their vascular supply for enhanced antitumor efficacy.
- Brand names
- AvastinMvasiZirabev
- Other names
- HS-20089HS20089HS 20089bevacizumab
02
Targets
TOP1 (DNA Topoisomerase I)VTCN1 (V-set domain containing T cell activation inhibitor 1)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on HS-20089 + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HS-20089 + bevacizumab.